Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
University of California, San Francisco
Wake Forest University Health Sciences
Centre hospitalier de l'Université de Montréal (CHUM)
Imperial College London
Rutgers, The State University of New Jersey
Mayo Clinic
Mayo Clinic
University of Michigan Rogel Cancer Center
Rutgers, The State University of New Jersey
Kaiser Permanente
Duke University
Mayo Clinic
University of Nebraska
M.D. Anderson Cancer Center
Medical College of Wisconsin
Mayo Clinic
RenJi Hospital
West China Hospital
UNC Lineberger Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Cancer Research UK
University of California, San Francisco
NuCana plc
University of Alabama at Birmingham
UNICANCER
The Christie NHS Foundation Trust
Universidade Federal de Pernambuco
Herning Hospital
Brown University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jules Bordet Institute
Universitair Ziekenhuis Brussel
Institut de cancérologie Strasbourg Europe
University Medical Center Groningen
QuantumLeap Healthcare Collaborative
Massachusetts General Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Western Sydney Local Health District
Technische Universität Dresden
Hospices Civils de Lyon
University of Chicago
Abramson Cancer Center at Penn Medicine
M.D. Anderson Cancer Center
Mayo Clinic
CureOne
University of Iowa
Herlev and Gentofte Hospital
Wake Forest University Health Sciences
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology